- In May 2024, BioElectronics Corporation, a leading innovator in wearable medical devices, announced expanded retail partnerships in the U.S. and Europe for its ActiPatch product line. These electromagnetic pulse therapy devices are designed for drug-free pain relief and are now available in major pharmacy chains, increasing consumer accessibility. This move reflects the company’s strategic focus on growing its global OTC footprint and addressing rising demand for non-invasive pain management solutions
- In April 2024, Oska Wellness, a U.S.-based medical technology company, introduced the Oska Pulse Gen3, a next-generation wearable EMP therapy device with improved battery life, enhanced portability, and app connectivity for personalized pain management. This product launch highlights Oska's dedication to user-centric innovation and reinforces its position in the growing wearable pain relief segment
- In March 2024, Orthometrix, Inc. entered a distribution agreement with a leading Asian wellness retail chain to introduce its Magcell PEMF therapy devices in high-demand markets such as India, Malaysia, and Singapore. The agreement aims to tap into the rising consumer interest in drug-free alternatives and expands the company’s presence across the Asia-Pacific region, one of the fastest-growing markets for home-use therapeutic technologies
- In February 2024, Curavi Health, a digital health and rehabilitation firm, launched its direct-to-consumer online platform offering subscription-based access to low-frequency PEMF therapy devices. These products cater to individuals managing chronic musculoskeletal pain and are designed for home use. This initiative supports the growing trend of digital health integration with wearable therapy and emphasizes the company’s commitment to accessible self-managed care solutions
- In January 2024, BEMER Group, a Switzerland-based company specializing in microcirculation therapy, unveiled clinical trial results showcasing the efficacy of its OTC PEMF devices in improving circulation and reducing pain in patients with osteoarthritis. The findings strengthen BEMER’s scientific credibility and support the clinical adoption of EMP therapy in broader wellness and home care applications
